Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics

The Lancet Respiratory Medicine

Volumn 3, Issue 11, 2015, Pages 888-900

  Mazur, Natalie I ^a   Martinón Torres, Federico ^b   Baraldi, Eugenio ^c   Fauroux, Brigitte ^d   Greenough, Anne ^e   Heikkinen, Terho ^f   Manzoni, Paolo ^g   Mejias, Asuncion ^h   Nair, Harish ⁱ   Papadopoulos, Nikolaos G ^j,k   Polack, Fernando P ^l   Ramilo, Octavio ^h   Sharland, Mike ^m   Stein, Renato ^n,o   Madhi, Shabir A ^p   Bont, Louis ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c Allergy and Respiratory Medicine Unit   (Italy)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g S ANNA HOSPITAL   (Italy)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF EDINBURGH   (United Kingdom)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k UNIVERSITY OF ATHENS   (Greece)

^l VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

ⁿ PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^o HOSPITAL FOR SICK CHILDREN   (Canada)

^p UNIVERSITY OF THE WITWATERSRAND   (South Africa)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASVASIRAN; BRONCHODILATING AGENT; CORTICOSTEROID; DANIRIXIN; F PROTEIN VACCINE; IMMUNOGLOBULIN; INACTIVATED VACCINE; INFUSION FLUID; LIVE VACCINE; MONOCLONAL ANTIBODY; MOTAVIZUMAB; NUCLEOSIDE ANALOG; PALIVIZUMAB; PRESATOVIR; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RIBAVIRIN; SMALL INTERFERING RNA; SODIUM CHLORIDE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT;

ASTHMA; BRONCHIOLITIS; CHILD DEATH; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TARGETING; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYDRATION; IMMUNIZATION; IMMUNOGENICITY; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MATERNAL CARE; MORBIDITY; MORTALITY; NASAL CANNULA; NEBULIZATION; OXYGENATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PLACENTAL TRANSFER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN DISEASE; SYSTEMATIC REVIEW (TOPIC); VACCINATION; VACCINE PRODUCTION; DISEASE MANAGEMENT; FEMALE; INFANT; MALE; NEWBORN; PRESCHOOL CHILD; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

ANTIVIRAL AGENTS; CHILD, PRESCHOOL; DISEASE MANAGEMENT; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RESPIRATORY TRACT INFECTIONS; VACCINATION;

EID: 84960077836     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00255-6     Document Type: Review

References (84)

1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015, 385:117-171. GBD 2013 Mortality and Causes of Death Collaborators.
2. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013, 368:1791-1799. the Dutch RSV Neonatal Network.
3. Glezen WP, Taber LH, Frank AL, Kasel JA Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543.
4. Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics 2014, 134:e1474-e1502. the American Academy of Pediatrics.
5. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999, 282:1440-1446.
6. Pelletier AJ, Mansbach JM, Camargo CA Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics 2006, 118:2418-2423.
7. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
8. Beigelman A, Bacharier LB The role of early life viral bronchiolitis in the inception of asthma. Curr Opin Allergy Clin Immunol 2013, 13:211-216.
9. Bacharier LB, Cohen R, Schweiger T, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2012, 130:91. e3.
10. Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010, 65:1045-1052.
11. Régnier SA, Huels J Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: systematic review and meta-analysis. Pediatr Infect Dis J 2013, 32:820-826.
12. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999, 354:541-545.
13. Zomer-Kooijker K, Uiterwaal CS, van der Gugten AC, Wilbrink B, Bont LJ, van der Ent CK Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infants. Eur Respir J 2014, 44:666-674.
14. Janssen R, Bont L, Siezen CL, et al. Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes. J Infect Dis 2007, 196:826-834.
15. Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Am J Respir Crit Care Med 2015, 191:34-44.
16. Escobar GJ, Masaquel AS, Li SX, Walsh EM, Kipnis P Persistent recurring wheezing in the fifth year of life after laboratory-confirmed, medically attended respiratory syncytial virus infection in infancy. BMC Pediatr 2013, 13:97.
17. Ducharme FM, Tse SM, Chauhan B Diagnosis, management, and prognosis of preschool wheeze. Lancet 2014, 383:1593-1604.
18. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
19. Moyes J, Cohen C, Pretorius M, et al. Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011. J Infect Dis 2013, 208(suppl 3):S217-S226.
20. Resch B, Manzoni P, Lanari M Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev 2009, 10:148-153.
21. Holman RC, Shay DK, Curns AT, Lingappa JR, Anderson LJ Risk factors for bronchiolitis-associated deaths among infants in the United States. Pediatr Infect Dis J 2003, 22:483-490.
22. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013, 132:e341-e348.
23. Thompson M, Vodicka TA, Blair PS, Buckley DI, Heneghan C, Hay AD Duration of symptoms of respiratory tract infections in children: systematic review. BMJ 2013, 347:f7027. the TARGET Programme Team.
24. Munywoki PK, Koech DC, Agoti CN, et al. Frequent asymptomatic infections during a respiratory syncytial virus epidemic in a rural Kenyan household cohort. J Infect Dis 2015, published online May 4, 2015. 10.1093/infdis/jiv263.
25. Gadomski AM, Scribani MB Bronchodilators for bronchiolitis. Cochrane Database Syst Rev 2014, 6. CD001266.
26. Fernandes RM, Bialy LM, Vandermeer B, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2013, 6. CD004878.
27. Hartling L, Bialy LM, Vandermeer B, et al. Epinephrine for bronchiolitis. Cochrane Database Syst Rev 2011, 6. CD003123.
28. Turner T, Wilkinson F, Harris C, Mazza D Evidence based guideline for the management of bronchiolitis. Aust Fam Physician 2008, 37:6-13. the Health for Kids Guideline Development Group.
29. Guideline 91: Bronchiolitis in children, a national clinical guideline Scottish Intercollegiate Guidelines Network, (accessed Sept 8, 2014). http://www.sign.ac.uk/pdf/sign91.pdf.
30. Bronchiolitis in children: NICE guideline, draft for consultation National Institute for Health and Care Excellence, (accessed Aug 15, 2015). http://www.nice.org.uk/guidance/ng9.
31. Florin TA, Shaw KN, Kittick M, Yakscoe S, Zorc JJ Nebulized hypertonic saline for bronchiolitis in the emergency department: a randomized clinical trial. JAMA Pediatr 2014, 168:664-670.
32. Wu S, Baker C, Lang ME, et al. Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial. JAMA Pediatr 2014, 168:657-663.
33. Sharma BS, Gupta MK, Rafik SP Hypertonic (3%) saline vs 0.93% saline nebulization for acute viral bronchiolitis: a randomized controlled trial. Indian Pediatr 2013, 50:743-747.
34. Everard ML, Hind D, Ugonna K, et al. SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis. Thorax 2014, 69:1105-1112. the SABRE Study Team.
35. Diagnosis and management of bronchiolitis. Pediatrics 2006, 118:1774-1793. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis.
36. Bressan S, Balzani M, Krauss B, Pettenazzo A, Zanconato S, Baraldi E High-flow nasal cannula oxygen for bronchiolitis in a pediatric ward: a pilot study. Eur J Pediatr 2013, 172:1649-1656.
37. Mayfield S, Bogossian F, O'Malley L, Schibler A High-flow nasal cannula oxygen therapy for infants with bronchiolitis: pilot study. J Paediatr Child Health 2014, 50:373-378.
38. Kang BJ, Koh Y, Lim C-M, et al. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intensive Care Med 2015, 41:623-632.
39. Esquinas AM, Parke R, Gifford AH Failure of high-flow nasal cannula and delayed intubation: a new harmful sequence?. Intensive Care Med 2015, 41:1170.
40. Schuh S, Freedman S, Coates A, et al. Effect of oximetry on hospitalization in bronchiolitis: a randomized clinical trial. JAMA 2014, 312:712-718.
41. Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490. GRADE working group.
42. Lenney W, Boner AL, Bont L, et al. Medicines used in respiratory diseases only seen in children. Eur Respir J 2009, 34:531-551.
43. Zhang L, Mendoza-Sassi RA, Wainwright C, Klassen TP Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst Rev 2013, 7. CD006458.
44. Parikh K, Hall M, Teach SJ Bronchiolitis management before and after the AAP guidelines. Pediatrics 2014, 133:e1-e7.
45. Nucleoproteins: National Library of Medicine- Medical Subject Headings MeSH Descriptor Data National Library of Medicine, (accessed May 24, 2015). http://www.nlm.nih.gov/cgi/mesh/2011/MB_cgi?mode=&term=Nucleoproteins.
46. BLAST Uniprot Consortium Phosphoprotein (accessed May 25, 2015). http://www.uniprot.org/keywords/KW-0597.
47. Graham BS, Anderson LJ Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 2013, 372:391-404.
48. Dubovsky F, Martinon-Torres F, Malkin E, et al. Randomized, double-blind placebo controlled study of the safety and immunogenicity of MEDI-534. 9th International Respiratory Syncytial Virus Symposium; Stellenbosch, South Africa; Nov 9-13, 2014; Poster 41.
49. Green C, Thomspon A, Sande C, et al. A novel RSV genetic vaccine based on simian Adenovirus and Modified Vaccinia virus Ankara encoding the RSV viral proteins F, N and M2-1 is safe and immunogenic in healthy adults. 9th International Respiratory Syncytial Virus Symposium; Stellenbosch, South Africa; Nov 9-13, 2014; Oral Presentation 41.
50. Glenn GM, Smith G, Fries L, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine 2013, 31:524-532.
51. Design I Immune Design's GLAAS discovery platform used in MEDI7510 phase 1 trial for respiratory syncytial virus (accessed March 10, 2015). http://www.immunedesign.com/wp-content/uploads/2014/05/Medi7510-GLAAS-FPI-2014_05_27.pdf.
52. Malkin E, Yogev R, Abughali N, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age. PLoS One 2013, 8:e77104.
53. Karron R, Luongo C, Thumar B, Loehr K, Collins PBU. Clinical evaluation of a live intranasal pediatric respiratory syncytial virus (RSV) vaccine based on deletion of the M2-2 ORF. 9th International Respiratory Syncytial Virus Symposium; Stellenbosch, South Africa; Nov 9-13, 2014; oral presentation 11.
54. Luongo C, Winter CC, Collins PL, Buchholz UJ Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol 2013, 87:1985-1996.
55. Luongo C, Winter CC, Collins PL, Buchholz UJ Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol 2012, 86:10792-10804.
56. Langley J, Aggarwal N, Halperin S, et al. A randomized, controlled, observer-blind phase I study of the safety, reactogenicity and immunogenicity of a single intramuscular dose of a respiratory syncytial virus vaccine adjuvanted with alum or non-adjuvanted, in healthy men 18-44 NCT01905215. 9th International Respiratory Syncytial Virus Symposium; Stellenbosch, South Africa; Nov 9-13, 2014. Oral presentation 114.
57. Falsey AR, Walsh EE, Mond JJ Polyclonal human intravenous immune globulin (IGIV) with high-levels of RSV neutralizing antibodies: a summary of animal and human studies. Annual Conference of the Canadian Blood and Marrow Transplant Group; Halifax NS, Canada; June 11-14, 2014 (accessed Aug 18, 2015). http://content.stockpr.com/admabiologics/db/Posters+and+Publications/924/file/CBMTG+Halifax+Poster+2014+Final+%282%29.pdf.
58. Devincenzo JP, Fathi H, MccLure M, et al. Treatment with oral ALS-8176, a nucleoside analog, rapidly reduces RSV viral load and clinical disease severity in a healthy volunteer challenge study. IDWeek 2014; Philadelphia, PA, USA; Oct 8-12, 2014; Late Breaker Oral Abstracts 1.
59. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008, 77:225-231.
60. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 2014, 371:711-722.
61. Depla E. Ablynx: Development of ALX-0170, an inhaled nanobody for the treatment of respiratory syncytial virus infection in infants. RSV Vaccines for the World; Porto, Portugal; Oct 14-16, 2013.
62. Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013, 57:6147-6153.
63. Understanding Nanobodies Ablynx, (accessed May 26, 2015). http://www.ablynx.com/technology-innovation/understanding-nanobodies/.
64. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537. Impact-RSV Study Group.
65. Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
66. Anderson LJ, Dormitzer PR, Nokes DJ, Rappuoli R, Roca A, Graham BS Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine 2013, 31(suppl 2):B209-B215.
67. Munywoki PK, Koech DC, Agoti CN, et al. The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya. J Infect Dis 2014, 209:1685-1692.
68. Empey KM, Peebles RS, Kolls JK Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis 2010, 50:1258-1267.
69. Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory. J Virol 2014, 88:10165-10176.
70. Swanson KA, Settembre EC, Shaw CA, et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 2011, 108:9619-9624.
71. de Haan L Modulation of Fc function: principles, preclinical challenges and translation to the clinic (accessed May 24, 2015). https://www.liv.ac.uk/media/livacuk/centrefordrugsafety/20110212HAAN.pdf.
72. Novavax announces positive top-line data from dose-confirmatory phase II clinical trial of its RSV caccine candidate in women of childbearing age Novavax, (accessed March 10, 2015). http://www.novavax.com/download/releases/NVAX%20M202%20Data%20Announcement%20PR%202014-04-28%20FINAL%20for%20Global%20Newswire.pdf.
73. Novavax Vaccine Technology Novavax, (accessed May 26, 2015). http://www.novavax.com/go.cfm?do=Page. View&pid=3.
74. Coler RN, Bertholet S, Moutaftsi M, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333.
75. Ramilo O, Lagos R, Sáez-Llorens X, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J 2014, 33:703-709.
76. Simon A, Karsten V, Cehelsky J, et al. Results of a phase 2b multi-center trial of ALN-RSV01 in respiratory syncytial virus (RSV)-infected lung transplant patients (accessed Aug 15, 2015). http://www.alnylam.com/web/wp-content/uploads/2012/08/ERS-RSV01-109-Poster-Final.pdf.
77. Teva Pharmaceuticals. Teva In-Focus respiratory webinar for the investment community focusing on Teva's R&D activities. Oct 8, 2013.
78. Miller BE, Smart K, Mistry S, et al. The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers. Eur J Drug Metab Pharmacokinet 2014, 39:173-181.
79. Gene IDN CXCR2 chemokine (C-X-C motif) receptor 2 [Homo sapiens (human)] (accessed May 24, 2015). http://www.ncbi.nlm.nih.gov/gene/3579.
80. McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013, 340:1113-1117.
81. Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013, 57:6147-6153.
82. Carbonell-Estrany X, Simões EAF, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010, 125:e35-e51. the Motavizumab Study Group.
83. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 2011, 17:1132-1135.
84. Hegele RG, Mastrangelo P, Moraes T Guanosine-rich oligonucleotide (gro) compostions, methods and uses for treating respiratory syncytial virus infection: WO 2013131182 A1 (accessed Dec 8, 2014). http://www.google.com/patents/WO2013131182A1?cl=en.